/images/ppid_59c68470-image-178134502873014719.webp)
/images/ppid_59c68470-image-17810950657314636.webp)
/images/ppid_a911dc6a-image-17810660841516401.webp)
/images/ppid_59c68470-image-17810726365455195.webp)
What is the story about?
Dr Reddy's Laboratories Ltd. has announced that it has launched Bosutinib Tablets, which are used in the treatment of Chronic Myeloid Leukaemia (CML).
The Hyderabad-based pharma company announced in an exchange filing that its Bosutinib Tablets 400mg, a generic equivalent of Bosulif, are in the United States
The company, which is also a Nifty 50 constituent, said that it has collaborated with MSN Laboratories Private Limited on this product.
Bosutinib is used to treat adults with Ph+ Chronic Myeloid Leukaemia (CML)
Dr Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.
Bosulif had US sales of approximately $253.8 million for the latest 12-month period that ended in April 2026.
The company is looking to expand its oncology portfolio and reinforce its commitment to improving patient access to affordable, high-quality medicines.
Speaking on the launch, Bharat Reddy, Executive Director, MSN Laboratories, added: “The successful development and commercialisation of Bosutinib Tablets demonstrates MSN’s strong scientific, regulatory, and manufacturing capabilities in complex oncology products. We remain committed to delivering high-quality, affordable medicines globally through efficient development and reliable manufacturing excellence.
When we take a look at the company stock, the shares of DRL slipped on Friday by 0.24%. This year so far, the price has seen a rise of 1.56% in value, taking the total value of each share to ₹1,272.90. The 52-week high mark stands at ₹1,379.70 per share.
Also Read: Anthropic disables Fable 5 and Mythos 5 after US government suspends all foreign access to models
The Hyderabad-based pharma company announced in an exchange filing that its Bosutinib Tablets 400mg, a generic equivalent of Bosulif, are in the United States
The company, which is also a Nifty 50 constituent, said that it has collaborated with MSN Laboratories Private Limited on this product.
Bosutinib is used to treat adults with Ph+ Chronic Myeloid Leukaemia (CML)
Dr Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.
Bosulif had US sales of approximately $253.8 million for the latest 12-month period that ended in April 2026.
The company is looking to expand its oncology portfolio and reinforce its commitment to improving patient access to affordable, high-quality medicines.
Speaking on the launch, Bharat Reddy, Executive Director, MSN Laboratories, added: “The successful development and commercialisation of Bosutinib Tablets demonstrates MSN’s strong scientific, regulatory, and manufacturing capabilities in complex oncology products. We remain committed to delivering high-quality, affordable medicines globally through efficient development and reliable manufacturing excellence.
When we take a look at the company stock, the shares of DRL slipped on Friday by 0.24%. This year so far, the price has seen a rise of 1.56% in value, taking the total value of each share to ₹1,272.90. The 52-week high mark stands at ₹1,379.70 per share.
Also Read: Anthropic disables Fable 5 and Mythos 5 after US government suspends all foreign access to models
/images/ppid_59c68470-image-178116507693930674.webp)
/images/ppid_59c68470-image-178117253564216696.webp)
/images/ppid_a911dc6a-image-178116758233837211.webp)
/images/ppid_59c68470-image-178119757594235680.webp)
/images/ppid_a911dc6a-image-178132855238952900.webp)
/images/ppid_59c68470-image-178123753723236356.webp)
/images/ppid_59c68470-image-178117506623119404.webp)